Nerviano becomes a targeted PARP player
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
